Tempest Therapeutics (TPST)
(Real Time Quote from BATS)
$2.19 USD
+0.02 (0.92%)
Updated Jul 12, 2024 10:04 AM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TPST 2.19 +0.02(0.92%)
Will TPST be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TPST based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TPST
Tempest (TPST) Up as First-Line Liver Cancer Study Meets Goals
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to Buy
TPST: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?
Bears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' Now
Other News for TPST
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), BioNTech SE (BNTX) and Tempest Therapeutics (TPST)
Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Gold Rises 1%; Accenture Shares Surge After Q3 Results
Tempest falls after new trial data for liver cancer therapy